Home / Tag Archives: incretin therapy (page 3)

Tag Archives: incretin therapy

GLP-1s and Autonomic Function: Understanding Heart Rate Changes in Clinical Practice

Medical illustration showing GLP-1 injection pens, ECG tracing, stethoscope, and anatomical heart model representing GLP-1 heart rate effects and autonomic function changes.

Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

Read More »

GLP-1s and Pancreatic Cancer: Reassessing Long-Term Safety Signals

Physician reviewing abdominal CT scan highlighting pancreas with GLP-1 injection pen on desk during clinical consultation

Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …

Read More »

Off-Ramp Planning for GLP-1s: When and How to Taper Without Losing Progress

Physician reviewing a gradual medication dose reduction chart with a patient during a consultation about GLP-1 tapering and metabolic health goals.

As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …

Read More »

GLP-1s and Hypertension: Can Incretins Help Bring Blood Pressure to Goal?

GLP-1 injection pen next to blood pressure monitor showing controlled systolic and diastolic readings

GLP-1–based therapies have quickly become a cornerstone of modern diabetes care. While most clinicians think of these agents for glucose lowering and weight loss, growing evidence suggests they may also support better blood pressure control. For patients living with diabetes and hypertension, that overlap raises an important question. Can GLP-1 …

Read More »

GLP‑1s in Menopause: Using Incretins to Protect Cardiometabolic Health in Midlife

Middle-aged woman smiling in a medical office, holding a medication bottle to represent GLP‑1 therapy during menopause.

Menopause marks a major transition in a woman’s life, defined not only by the end of menstrual cycles but also by profound hormonal and metabolic changes. One often under‑recognized shift is the acceleration of cardiometabolic risk. Women in midlife frequently experience increased central adiposity, changes in glucose regulation, rising blood …

Read More »

GLP‑1s and Bone Health: Do Incretins Protect or Put Patients at Risk?

Illustration showing a glowing skeleton, GLP‑1 medications, porous bone models, and a balance scale highlighting bone health risks.

Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have transformed type 2 diabetes management by improving blood sugar control and promoting weight loss. Yet as clinical use grows, so does interest in how GLP‑1 medications affect skeletal health — particularly their impact on bone density, remodeling, and fracture risk. This article unpacks …

Read More »